Maxim Kebenko

797 total citations
30 papers, 609 citations indexed

About

Maxim Kebenko is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Maxim Kebenko has authored 30 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Maxim Kebenko's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Glycosylation and Glycoproteins Research (6 papers) and Phagocytosis and Immune Regulation (6 papers). Maxim Kebenko is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Glycosylation and Glycoproteins Research (6 papers) and Phagocytosis and Immune Regulation (6 papers). Maxim Kebenko collaborates with scholars based in Germany, United States and Spain. Maxim Kebenko's co-authors include Walter Fiedler, Angelika Harneit, Joachim M. Weitzel, M. Wolf, Ruth Seggewiss‐Bernhardt, Barbara Ritter, Sabine Stienen, Michael Heuser, Matthias Friedrich and Annette Hasenburg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Molecular Sciences.

In The Last Decade

Maxim Kebenko

29 papers receiving 591 citations

Peers

Countries citing papers authored by Maxim Kebenko

Since Specialization

Citations

This map shows the geographic impact of Maxim Kebenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maxim Kebenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maxim Kebenko more than expected).

Fields of papers citing papers by Maxim Kebenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maxim Kebenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maxim Kebenko. The network helps show where Maxim Kebenko may publish in the future.

Co-authorship network of co-authors of Maxim Kebenko

This figure shows the co-authorship network connecting the top 25 collaborators of Maxim Kebenko. A scholar is included among the top collaborators of Maxim Kebenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maxim Kebenko. Maxim Kebenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Functional Role of Fatty Acid Synthase for Signal Transduction in Core-Binding Factor Acute Myeloid Leukemia with an Activating c-Kit Mutation 2025 ·Biomedicines ·(unknown), (unknown), (unknown), Anna Worthmann, Stefan Horn, (unknown), Cyrus Khandanpour, Niklas Gebauer, Sivahari Prasad Gorantla, (unknown), Hartmut Schlüter, Malte Kriegs, Walter Fiedler, Carsten Bokemeyer, Manfred Jücker, Maxim Kebenko	1
2	Effectiveness of high efficiency particulate (HEPA) air condition combined with the antifungal prophylaxis on incidence, morbidity and mortality of invasive fungal infections in patients with acute myeloid leukemia: a retrospective single-center study 2024 ·Frontiers in Oncology ·(unknown), Eik Vettorazzi, Walter Fiedler, Holger Rohde, Jannik Stemler, (unknown), Carsten Bokemeyer, Cyrus Khandanpour, (unknown), Maxim Kebenko	0
3	Multidisciplinary survey on use of feeding tubes in head and neck cancer patients undergoing chemoradiotherapy in Germany—the SUFEETUBE project 2024 ·Strahlentherapie und Onkologie ·(unknown), Alexander Fabian, Alexander Rühle, Alexander Thieme, (unknown), Lukas Käsmann, (unknown), (unknown), Tamer Soror, (unknown), (unknown), Maxim Kebenko, Christoph Seidel, (unknown), Linda Krause, Karl‐Ludwig Bruchhage, Dirk Rades	1
4	1496P Trabectedin for patients with advanced soft tissue sarcoma: A non-interventional, prospective, multicenter study 2022 ·Annals of Oncology ·Viktor Grünwald, Daniel Pink, Gerlinde Egerer, Enrico Schalk, Marinela Augustin, (unknown), (unknown), Dietmar Reichert, Maxim Kebenko, (unknown), D Hahn, (unknown), Mathias Hoiczyk, (unknown), Lars Hanker, Dirk Hempel, María José Pontes, (unknown), Philipp Ivanyi	1
5	Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors 2022 ·ESMO Open ·Sebastian Ochsenreither, Walter Fiedler, (unknown), Marina Macchini, Ignacio Matos, (unknown), (unknown), Francesco Raspagliesi, Domenica Lorusso, Ulrich Keilholz, Christina C. Rolling, Maxim Kebenko, Konrad Klinghammer, Omar Saavedra, Harald Baumeister, Alfredo Zurlo, Elena Garralda	8
6	Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient® in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06) 2021 ·Cancers ·Daniel Pink, Dimosthenis Andreou, Sebastian Bauer, Thomas Brodowicz, Bernd Kasper, Peter Reichardt, Stephan Richter, Lars H. Lindner, Joanna Szkandera, Viktor Grünwald, Maxim Kebenko, Marietta Kirchner, Peter Hohenberger	18
7	Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors 2020 ·European Journal of Cancer ·Marina Macchini, Elena Garralda, Walter Fiedler, Gianluca Del Conte, Christina C. Rolling, Maxim Kebenko, Konrad Klinghammer, (unknown), (unknown), Harald Baumeister, Alfredo Zurlo, (unknown)	1
8	Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS 2018 ·Blood ·Sonja Loges, Michael Heuser, (unknown), Carlos E. Vigil, Peter Paschka, Isabel Ben‐Batalla, Nuray Akyüz, David Micklem, Robert A. Holt, (unknown), James B. Lorens, Murray Yule, Maxim Kebenko, Melanie Janning, Mascha Binder, Walter Fiedler, Jörge E. Cortes, Bjørn Tore Gjertsen	7
9	The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors 2018 ·Annals of Oncology ·Elena Garralda, (unknown), Sebastian Ochsenreither, Luca Gianni, Domenica Lorusso, Walter Fiedler, Ulrich Keilholz, Konrad Klinghammer, Christina Dicke, Maxim Kebenko, Ignacio Matos, Josep Tabernero, Francesco Raspagliesi, (unknown), (unknown), Harald Baumeister, Alfredo Zurlo	1
10	Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma 2018 ·Annals of Oncology ·(unknown), Walter Fiedler, Jobst C. von Einem, Henk M.W. Verheul, T Seufferlein, (unknown), Volker Heinemann, Maxim Kebenko, C. Willemien Menke‐van der Houven van Oordt, Thomas J. Ettrich, Erik Rasmussen, Paul N. Bogner, (unknown), Sabine Stienen, Elisabeth G.E. de Vries	18
11	Axl blockade in vitro and in patients with high-risk MDS by the small molecule inhibitor BGB324. 2017 ·Journal of Clinical Oncology ·Sonja Loges, Isabel Ben‐Batalla, Michael Heuser, (unknown), Thomas Schroeder, Stefanie Geyh, David Micklem, Jörg Chromik, Maxim Kebenko, Walter Fiedler, Murray Yule, Jörge E. Cortes, Bjørn Tore Gjertsen	2
12	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia 2016 ·Oncotarget ·Norbert Vey, Jacques Delaunay, Giovanni Martinelli, Walter Fiedler, Emmanuel Raffoux, Thomas Prébet, Carlos Gomez‐Roca, Cristina Papayannidis, Maxim Kebenko, Peter Paschka, R D Christen, Ernesto Guarin, Ann-Marie E Bröske, Monika Baehner, Michael Brewster, Antje‐Christine Walz, Francesca Michielin, Valeria Runza, Valérie Méresse, Christian Récher	73
13	Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study 2015 ·Blood ·Walter Fiedler, Jörg Chromik, Maxim Kebenko, Felicitas Thol, Arne Trummer, (unknown), Christian Brandts, Anne Köhler, (unknown), Carsten Bokemeyer, Susann Theile, (unknown), Michael Heuser	3
14	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations 2015 ·British Journal of Haematology ·Walter Fiedler, Sabine Käyser, Maxim Kebenko, Melanie Janning, Jürgen Krauter, Marcus M. Schittenhelm, Katharina S. Götze, Daniela Weber, Gudrun Göhring, Veronica Teleanu, Felicitas Thol, Michael Heuser, Konstanze Döhner, Arnold Ganser, Hartmut Döhner, Richard F. Schlenk	82
15	ErbB2 signaling activates the Hedgehog pathway via PI3K–Akt in human esophageal adenocarcinoma: Identification of novel targets for concerted therapy concepts 2014 ·Cellular Signalling ·Maxim Kebenko, Astrid Drenckhan, Stephanie J. Gros, Manfred Jücker, Nicole Grabinski, Florian Ewald, Astrid Grottke, Alexander Schultze, Jakob R. Izbicki, Carsten Bokemeyer, Jasmin Wellbrock, Walter Fiedler	41
16	Favorable Outcome in a Large Cohort of Prospectively Treated Adult Patients with T-Lymphoblastic Lymphoma (T-LBL) Despite Slowly Evolving Complete Remission Assessed By Conventional Radiography 2014 ·Blood ·Nicola Gökbuget, Andrea Wolf, Matthias Stelljes, Andreas Hüttmann, Eike C. Buss, Andreas Viardot, (unknown), Maike de Wit, Norbert Frickhofen, Maxim Kebenko, Mustafa Kondakci, Doris Kraemer, Stefan Schwartz, Hubert Serve, Karsten Spiekermann, Reingard Stuhlmann, Albrecht Reichle, Dieter Hoelzer	18
17	A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. 2012 ·Journal of Clinical Oncology ·Walter Fiedler, M. Wolf, Maxim Kebenko, Marie-Elisabeth Goebeler, Barbara Ritter, Alexander Quaas, (unknown), Youssef Hijazi, (unknown), Matthias G. Friedrich, Peter Kufer, Stanley Frankel, Ruth Seggewiss‐Bernhardt, (unknown)	33
18	Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653) 2012 ·Blood ·Walter Fiedler, Sabine Käyser, Maxim Kebenko, Jürgen Krauter, Helmut R. Salih, Katharina S. Götze, Daniela Späth, Gudrun Göhring, Veronica Teleanu, Konstanze Döhner, Arnold Ganser, Hartmut Döhner, Richard F. Schlenk	10
19	The role of thyroid hormone receptor DNA binding in negative thyroid hormone-mediated gene transcription 2008 ·Journal of Molecular Endocrinology ·(unknown), (unknown), Maxim Kebenko, (unknown), Angelika Harneit, J. Merz, Joachim M. Weitzel	12
20	T3-mediated expression of PGC-1α via a far upstream located thyroid hormone response element 2008 ·Molecular and Cellular Endocrinology ·(unknown), Angelika Harneit, (unknown), Maxim Kebenko, (unknown), Joachim M. Weitzel	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact